Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McNeil OTC Recalls Slice $900M From J&J's 2010 Sales

This article was originally published in The Tan Sheet

Executive Summary

Recalled OTC drugs took a $900 million bite out of Johnson & Johnson's fiscal 2010 sales, including $300 million in the fourth quarter, contributing to what the company and analysts labeled disappointing earnings.

You may also be interested in...



J&J Plans To Upgrade Recalled OTCs for Relaunch

Johnson & Johnson plans to return recalled OTC drugs to the market with innovations designed to strengthen consumer trust, VP of Finance and CFO Dominic Caruso said during a presentation at the Deutsche Bank Securities Health Care Conference.

J&J Plans To Upgrade Recalled OTCs for Relaunch

Johnson & Johnson plans to return recalled OTC drugs to the market with innovations designed to strengthen consumer trust, VP of Finance and CFO Dominic Caruso said during a presentation at the Deutsche Bank Securities Health Care Conference.

J&J Plans To Upgrade Recalled OTCs for Relaunch

Johnson & Johnson plans to return recalled OTC drugs to the market with innovations designed to strengthen consumer trust, VP of Finance and CFO Dominic Caruso said during a presentation at the Deutsche Bank Securities Health Care Conference.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel